170 related articles for article (PubMed ID: 26123235)
1. Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country.
Alam-mehrjerdi Z; Mokri A; Dolan K
Asian J Psychiatr; 2015 Aug; 16():17-25. PubMed ID: 26123235
[TBL] [Abstract][Full Text] [Related]
2. Methamphetamine dependence in methadone treatment services in Iran: the first literature review of a new health concern.
Alammehrjerdi Z; Ezard N; Dolan K
Asian J Psychiatr; 2018 Jan; 31():49-55. PubMed ID: 29414387
[TBL] [Abstract][Full Text] [Related]
3. Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country.
Alam-Mehrjerdi Z; Abdollahi M; Higgs P; Dolan K
Asian J Psychiatr; 2015 Aug; 16():78-83. PubMed ID: 26168763
[TBL] [Abstract][Full Text] [Related]
4. Meth/amphetamine use and associated HIV: Implications for global policy and public health.
Degenhardt L; Mathers B; Guarinieri M; Panda S; Phillips B; Strathdee SA; Tyndall M; Wiessing L; Wodak A; Howard J;
Int J Drug Policy; 2010 Sep; 21(5):347-58. PubMed ID: 20117923
[TBL] [Abstract][Full Text] [Related]
5. The Persian methamphetamine use in methadone treatment in Iran: implication for prevention and treatment in an upper-middle income country.
Alam-Mehrjerdi Z; Abdollahi M
Daru; 2015 Nov; 23():51. PubMed ID: 26578071
[TBL] [Abstract][Full Text] [Related]
6. Factors Influencing Transition to Shisheh (Methamphetamine) among Young People Who Use Drugs in Tehran: A Qualitative Study.
Noroozi A; Malekinejad M; Rahimi-Movaghar A
J Psychoactive Drugs; 2018; 50(3):214-223. PubMed ID: 29377788
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and public health Consequences of methamphetamine use in California's Central Valley.
Gibson DR; Leamon MH; Flynn N
J Psychoactive Drugs; 2002; 34(3):313-9. PubMed ID: 12422943
[TBL] [Abstract][Full Text] [Related]
8. Methamphetamine use and methadone maintenance treatment: an emerging problem in the drug addiction treatment network in Iran.
Shariatirad S; Maarefvand M; Ekhtiari H
Int J Drug Policy; 2013 Nov; 24(6):e115-6. PubMed ID: 23773684
[No Abstract] [Full Text] [Related]
9. Initiation into methamphetamine use: qualitative findings from an exploration of first time use among a group of New Zealand users.
Sheridan J; Butler R; Wheeler A
J Psychoactive Drugs; 2009 Mar; 41(1):11-7. PubMed ID: 19455905
[TBL] [Abstract][Full Text] [Related]
10. [Prevalence and Therapy of Crystal Methamphetamine Dependence].
Soyka M; Koller G; Proebstl L; Kamp F; Franke A; Schmidt P; Baumgärtner G; Schacht-Jablonowsky M; Sievert A; Straif M; Hamdorf W
Fortschr Neurol Psychiatr; 2017 Feb; 85(2):92-99. PubMed ID: 28235211
[TBL] [Abstract][Full Text] [Related]
11. HIV Programs in Iran (Persia), Iraq and Saudi Arabia: A Brief Review of Current Evidence in West and Southwest Asia.
Massah O; Moradi A; Farhoudian A; Amini-Lari M; Joulaei H; Daneshmand R
Addict Health; 2016 Jul; 8(3):136-144. PubMed ID: 28496952
[TBL] [Abstract][Full Text] [Related]
12. Methamphetamine and cardiovascular pathology: a review of the evidence.
Kaye S; McKetin R; Duflou J; Darke S
Addiction; 2007 Aug; 102(8):1204-11. PubMed ID: 17565561
[TBL] [Abstract][Full Text] [Related]
13. Methamphetamine abuse.
Winslow BT; Voorhees KI; Pehl KA
Am Fam Physician; 2007 Oct; 76(8):1169-74. PubMed ID: 17990840
[TBL] [Abstract][Full Text] [Related]
14. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran.
Nikfarjam A; Shokoohi M; Shahesmaeili A; Haghdoost AA; Baneshi MR; Haji-Maghsoudi S; Rastegari A; Nasehi AA; Memaryan N; Tarjoman T
Int J Drug Policy; 2016 May; 31():147-52. PubMed ID: 26980349
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of psychotic symptoms among methamphetamine users.
McKetin R; McLaren J; Lubman DI; Hides L
Addiction; 2006 Oct; 101(10):1473-8. PubMed ID: 16968349
[TBL] [Abstract][Full Text] [Related]
16. Crystalline methamphetamine use and methamphetamine-related harms in Australia.
Degenhardt L; Sara G; McKetin R; Roxburgh A; Dobbins T; Farrell M; Burns L; Hall WD
Drug Alcohol Rev; 2017 Mar; 36(2):160-170. PubMed ID: 27286742
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and factors associated with methamphetamine use among adult substance abusers.
Barati M; Ahmadpanah M; Soltanian AR
J Res Health Sci; 2014; 14(3):221-6. PubMed ID: 25209911
[TBL] [Abstract][Full Text] [Related]
18. Beyond methamphetamine: Documenting the implementation of the Matrix model of substance use treatment for opioid users in a South African setting.
Magidson JF; Gouse H; Burnhams W; Wu CY; Myers B; Joska JA; Carrico AW
Addict Behav; 2017 Mar; 66():132-137. PubMed ID: 27940387
[TBL] [Abstract][Full Text] [Related]
19. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm.
Kinner SA; Degenhardt L
Drug Alcohol Rev; 2008 May; 27(3):292-300. PubMed ID: 18368611
[TBL] [Abstract][Full Text] [Related]
20. Health outcomes associated with methamphetamine use among young people: a systematic review.
Marshall BD; Werb D
Addiction; 2010 Jun; 105(6):991-1002. PubMed ID: 20659059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
